Presidential Candidates Mandate
"Paperless Healthcare Initiative"-
Opening Door for One Company's
Technology to be Used In 2,250 American
Hospitals
"I believe we'll make 50% gains in 18 months – while collecting a 7% dividend with this company."
– Dr. George Huang
Regardless which candidate you vote for in November – all three have laid out plans to promote "paperless" medical technology. One small company stands to benefit the most from this push.
It has already installed the technology in 600 hospitals in 46 states across the country...
And there's the potential for this company to begin installation in the remaining 2,250 hospitals in the very near future.
How do we know? Because all three candidates have said so in their own words:Barack Obama: "[I] will invest $10 billion a year over the next five years to move the U.S. health care system to broad adoption of [paperless records]."
John McCain: "[I will] promote rapid deployment of [paperless healthcare records]."
Hillary Clinton: "[I will] institute a new Paperless Health Information Technology System... An up-front and phased-out $3 billion a year investment fund would be provided to help hospitals and doctor's offices adopt and implement [this system]."
In short, this technology allows hospitals to integrate and manage every single procedure and prescription – down to the last bandage – into one simple computer system.
There's no wasteful printouts, no sloppy physician signatures, and a drastic cutback on human error.
So it's easy to see why this technology is being fast-tracked into hundreds of hospitals every day...
With hospitals already flocking to this technology, our resident biotech researcher Rob Fannon believes this company will see at least 50% gains in the near future.
In the meantime, the company pays out a healthy 7% dividend.Rob covers the story in full in his newest Phase 1 Investor research report "The World's Best Health Care IT."
And this Friday, April 4th, Phase 1 editors Rob Fannon and Dr. George Huang have scheduled a private conference call with executives from this company.
If this sounds like something you're interested in, let me tell you more about Phase 1 so you can decide for yourself whether or not to join us...
Is our most exclusive
research service right for you?
Typically in Phase 1 Investor we focus on small biotech stocks. That's because biotech offers the potential for extremely large gains.
Look at the track records of our editors over the years and you'll see that almost all of our really big winners come from the biotech arena:- There's Elan Pharmaceuticals, which some subscribers used to make more than 206%...
- Sirna Therapeutics, which we closed with a 203% gain...
- Celgene, which made some readers 233%, and...
- ID Biomedical, which helped some of our subscribers pocket a 331% gain.
Biotech – unlike most other sectors – is very hard to analyze.
You have to look at more than just the financials. You need to understand the science too. In fact, if you don't understand both, there's little chance for success.
That's why the profit potential is so big and why so few people can do it.
Which is why we hired Rob Fannon and Dr. George Huang from Johns Hopkins University.Rob came to us about two years ago. He studied physiology and biochemistry as an undergrad and then earned two advanced degrees from John Hopkins University, one of the top medical colleges in the country.
Rob has also had extensive lab and field experience.
He worked as a lab technician at a company called Bioserve. There he conducted a series of genetic research projects for the National Institute of Health. He was also a researcher at Cedars-Sinai Medical Center in Los Angeles in the hospital's Comprehensive Prostate Cancer Research Program.And although Rob's only been "officially" on our staff for about two years, he's actually been our secret contact for many of our best medical and biotech recommendations for close to five.
And every time he's told me he's sure a new medical technology will work, it has. In short, Rob is the best biotech and medical analyst I've ever come across.
Rob even hired a research analyst named Dr. George Huang to work at his side – solely for the purpose of locating biotech breakthroughs.
George's specialty is getting exclusive information from top universities... labs... and venture capital firms for new technologies in the health sector. (He holds a Ph.D. from Johns Hopkins School of Medicine, where he worked under a 2003 Nobel Laureate in Chemistry... speaks three languages... worked for a Canadian biotech investment firm... and is published in the four best journals of his field.)We pay a premium for Rob and George's specialized knowledge – and we spend a fortune sending them around the world to investigate companies first hand. This is why Phase 1 Investor is our most expensive research service. And it's already helped some of our readers make a lot of money...
For instance, Rob uncovered a company called Crucell. It's a small medical company which developed a safer and faster vaccination technology. To date, Crucell is up over 126%.
He also recommended a company called Esperion. They had developed a radical new way to treat heart disease. Rob's expertise and connections on this recommendation was crucial. In a previous position he was introduced to the company when he worked in a lab down the hall from one of the lead clinical researchers for Esperion. Readers who acted on Rob's recommendation had the chance to make 53% gains overnight when the company was sold to Pfizer.
Opportunities like Crucell and Esperion don't just happen. It takes weeks of analysis, meetings with corporate management, thorough readings of current scientific and technology journals, as well as interviews with independent experts.But when Rob and George do find these early-stage, BIG IDEA companies it's well worth it. These are the companies that change the face of business... and have the potential to grow 500% to 1,000% – or more.
That's usually what we end up covering in Phase 1 – the most promising biotech opportunities in the market – like the tiny company Rob recently published his report about.
If you'd like to get access to this report all you need to do is take a risk-free trial subscription to Phase 1 Investor today.
|
But you should know that Phase 1 Investor is different from everything else we do here at S&A Research.
In fact, the kind of investing we write about is not for most people. And honestly, that's why it's so successful.
Phase 1 is designed for a very small group of aggressive – but prudent – individuals who want to make serious money.
Our typical subscriber has already had a good deal of investment success. And they are willing to pay a bit more money to access the types of research and opportunities we cover in Phase 1.
Simply put, this is our elite service – the very best investment ideas for our most serious subscribers.
These are the kinds of investments that can literally change your life – where an investment of $10,000 could turn into a full year's salary within a few weeks time... The kind that would literally allow you to QUIT WORK forever.
It happens all the time – you just have to know about the RIGHT company at the RIGHT time... with help from the experts directly involved.
Finding those types of opportunities takes a great deal of analysis and most often the right "inside connections."
My point is, when you're dealing with small, volatile biotech stocks, it's important to have high-powered contacts inside the industry...
And that's exactly what we have with this month's Phase 1 recommendation.
One full year of Phase 1 Investor costs $5,000. It's not cheap – and there are two good reasons for this price:
| This is among the most expensive research we do at S&A. It's annual production costs are steep(including overhead, travel expenses, and subscriptions to financial services). It's the only service where we have 2 (sometimes 3) analysts working on each month's recommendation. | |
| Because we focus on tiny, tiny companies – with the potential for the biggest gains – the $5,000 price ensures that only the most serious-minded individuals are reaping the rewards. | |
We realize that $5,000 is a sizeable sum of money... which is why we offer a dozen other services at S&A that are more affordable.
In short, Phase 1 is only for our most seasoned subscribers... the kind of folks who are willing to consider taking significant risks with volatile micro-cap stocks in order to make potential gains of 1,000% or more.
If this sounds like your type of investment opportunity, here's what I recommend you do:
| Sign up right now for a trial subscription to Rob Fannon's Phase 1 Investor. Within the next 15 minutes, you will have access to this month's report "The World's Best Health Care IT"– and everything else Rob and George have published for Phase 1. | |
| If you decide Phase 1 isn't for you, simply cancel your subscription before your 3-month trial period is up. I'll send you a full refund – 100% – no questions asked. After that, you'll receive a prorated refund on the unused portion of your subscription. | |
If you're interested in giving our elite research service a try... and getting this month's pick absolutely free... I suggest you sign up right away.
For more information and to get started Subscribe Now .Sincerely,
George Rayburn
Executive Director, S&A Research
April 2008
P.S. If you take advantage of this online offer you can take an additional 10% off the one-year subscription price of $5,000 – that's $4,500 – or just $1,300 quarterly.